Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Targets |
NF-κB; IKK
|
---|---|
ln Vitro |
NF-κB-IN-1 (compound 17) (0.001-100 μM; 72 h) has GI50s of 0.72, 0.07, 0.13, and 0.16 μM, respectively, and inhibits the growth of A549, H1944, H460, and H157 cells for 72 hours[1].
IκB phosphorylation and degradation in A549 cells are effectively blocked by NF-κB-IN-1 (0.5–25 μM; pretreated for 30 min. or 4 h.)[1]. NF-κB-IN-1 (0.1-100 μM; pretreated for 30 min) inhibits TNFα-induced nuclear translocation of NF-B in A549 cells in a dose-dependent manner, with an IC50 of 1.0 μM[1]. The clonogenic activity of lung cancer is inhibited by NF-κB-IN-1 (0.1-0.4 μM; 9 d)[1]. |
References |
Molecular Formula |
C31H30O8
|
---|---|
Molecular Weight |
530.565109729767
|
Exact Mass |
530.194
|
CAS # |
1227098-15-8
|
Related CAS # |
1227098-15-8
|
PubChem CID |
49851904
|
Appearance |
Light yellow to yellow solid
|
LogP |
5.6
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
8
|
Rotatable Bond Count |
12
|
Heavy Atom Count |
39
|
Complexity |
826
|
Defined Atom Stereocenter Count |
0
|
SMILES |
COC1=C(C=C(C=C1)/C=C/C(=O)C(=CC2=CC(=C(C=C2)O)OC)C(=O)/C=C/C3=CC(=C(C=C3)OC)OC)OC
|
InChi Key |
AYIYVEPNEPUJCF-GNXRPPCSSA-N
|
InChi Code |
InChI=1S/C31H30O8/c1-35-27-14-9-20(17-30(27)38-4)6-11-24(32)23(16-22-8-13-26(34)29(19-22)37-3)25(33)12-7-21-10-15-28(36-2)31(18-21)39-5/h6-19,34H,1-5H3/b11-6+,12-7+
|
Chemical Name |
(1E,6E)-1,7-bis(3,4-dimethoxyphenyl)-4-[(4-hydroxy-3-methoxyphenyl)methylidene]hepta-1,6-diene-3,5-dione
|
Synonyms |
CHEMBL1800965; NF-κB-IN-1; NF-kappaB-IN-1; NF-|EB-IN-1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 50 mg/mL (94.2 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8848 mL | 9.4238 mL | 18.8477 mL | |
5 mM | 0.3770 mL | 1.8848 mL | 3.7695 mL | |
10 mM | 0.1885 mL | 0.9424 mL | 1.8848 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.